Effectiveness of Umonium38 against Burkholderia pseudomallei, Escherichia coli, Pseudomonas aeruginosa and Methicillin-Resistant Staphylococcus aureus (MRSA)

BMC Infect Dis. 2024 Feb 16;24(1):212. doi: 10.1186/s12879-024-09102-9.

Abstract

Aims: We investigated the antibacterial efficacy of Umonium38 and Virkon® against Burkholderia pseudomallei, Escherichia coli, Pseudomonas aeruginosa and Methicillin-Resistant Staphylococcus aureus (MRSA) up to 14 days following treatment.

Methods and results: Umonium38 was diluted to 0.5%, 1.0%, 1.5%, 2.0%, 2.5% and 3%, tested against the bacterial strains at various contact times (15 min to 24 h), and incubated for up to 14 days. A minimum concentration of 0.5% Umonium38 with a contact time of 15 min effectively killed approximately 108 CFU/ml of all four bacterial species. No growth was observed on agar plates from day 0 until day 14 for all six concentrations. The bacteria were also inactivated by a 30-minute treatment time using Virkon® 1% solution.

Conclusions: Umonium38 effectively inactivates B. pseudomallei, E. coli, P. aeruginosa and MRSA at a concentration of ≥ 0.5% with a contact time of at least 15 min. The antimicrobial effect of Umonium38 remained for 14 days.

Keywords: Bacterial viability; Disinfectant; Umonium38; Virkon.

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Bacteria
  • Burkholderia pseudomallei*
  • Escherichia coli
  • Humans
  • Methicillin-Resistant Staphylococcus aureus*
  • Microbial Sensitivity Tests
  • Peroxides*
  • Pseudomonas aeruginosa
  • Sulfuric Acids*

Substances

  • monoperoxysulfate
  • Anti-Bacterial Agents
  • Peroxides
  • Sulfuric Acids